J&J inks an­oth­er Ste­lara biosim­i­lar set­tle­ment, push­ing Formy­con’s can­di­date in­to po­ten­tial 2025 launch

An­oth­er biosim­i­lar ver­sion of John­son & John­son’s Ste­lara has been de­layed af­ter the phar­ma gi­ant inked a new agree­ment with two Eu­ro­pean drug­mak­ers de­vel­op­ing a biosim­i­lar ver­sion of J&J’s top-sell­ing drug.

Formy­con and Fre­se­nius Kabi an­nounced the set­tle­ment Mon­day morn­ing, say­ing that their ex­per­i­men­tal biosim­i­lar can­di­date to Ste­lara is set to be launched in the US by April 15, 2025.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER